We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 160

Middle District of Florida Employs Unique Provisions for False Claims Act Settlements with Compounding Pharmacies
  • Phelps Dunbar LLP
  • USA
  • May 2 2017

During the last three years, the U.S. Attorney for the Middle District of Florida ("the District") settled a number of False Claims Act investigations

Office of Insurance Regulation approves workers’ compensation rate increase
  • Holland & Knight LLP
  • USA
  • November 4 2011

On October 24, 2011, Florida Insurance Commissioner Kevin McCarty approved a proposed 8.9 percent rate hike requested by the National Council on Compensation Insurance.

FDA lacks authority to enjoin traditional animal drug compounding
  • King & Spalding LLP
  • USA
  • September 19 2011

On September 12, 2011, the United States District Court for the Middle District of Florida entered an order denying the U.S. Food and Drug Administration’s request for an injunction barring Franck’s Lab, a Floridabased pharmacy, from engaging in traditional, state-licensed bulk compounding of animal drugs and granting Franck’s motion for summary judgment.

Pharmaceutical representatives as exempt? Contrary to the 3rd and 9th Circuits, a Florida District Court enters the fray
  • Seyfarth Shaw LLP
  • USA
  • July 18 2011

On July 12, 2011, a federal district court in the Southern District of Florida jumped into the divide over whether pharmaceutical representatives are exempt from the FLSA’s overtime requirements.

House proposes to end prescription drug database
  • Foley & Lardner LLP
  • USA
  • March 14 2011

The House Health and Human Services Committee voted out two proposed committee bills on Thursday that will repeal the state's prescription drug database and prohibit the dispensing of controlled substances by physicians.

A tale of two cases: the extent to which a New Jersey trial court disregarded a Florida appellate court’s decision and the continued viability of the learned intermediary doctrine in New Jersey
  • Sills Cummis & Gross PC
  • USA
  • August 26 2010

Can a New Jersey trial court, applying the law of another jurisdiction, disregard an intermediate appellate decision from that other jurisdiction that is directly on point?

OIG report on inhalation drugs in South Florida
  • Reed Smith LLP
  • USA
  • April 24 2009

According to a new OIG review, Medicare spent an average of five times more per beneficiary on inhalation drugs in South Florida compared to the rest of the country, with the greatest spending differences attributable to the more expensive brand name drugs levalbuterol and budesonide.